



Express Mail No.: EV 535 904 243 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Bhagwat et al.

Confirmation No.: 1280

Serial No.: 10/673,121

Group Art Unit: 1617

Filed: September 26, 2003

Examiner: Kim, Jennifer M.

For: INDAZOLE DERIVATIVES AS JNK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO  
Attorney Docket No.: 10624-133-999  
(CAM: 700755-999132)

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97**

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or might be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **A01-A07**, which are listed on the accompanying Substitute for Form 1449/PTO entitled "Information Disclosure Statement By Applicant." A copy of references **A01-A07** are submitted herewith.

Identification of the listed references is not to be construed as an admission that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review references **A01-A07** and make them of record in the file history of the above-identified application by initializing the attached Substitute for Form 1449/PTO entitled "Information Disclosure Statement By Applicant."

As this Supplemental Information Disclosure Statement is being submitted before the mailing of any final action under § 1.113, a notice of allowance under § 1.311, or an

08/29/2006 RMEBRAHT 00000066 503013 10673121

01 FC:1806 180.00 DA

ATI-2233123v1

action that otherwise closes prosecution in the application, it is estimated that a fee of \$180.00 is due pursuant to 37 C.F.R. §§ 1.97(c)(2) and 1.17(p). Please charge the required fee to Jones Day Deposit Account No. 50-3013. Should the Patent and Trademark Office determine that any additional fee is required, please charge the required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this document is enclosed for accounting purposes.

Date: August 24, 2006

Respectfully submitted,

*Anthony M. Insogna, Reg. No. 35,203*

*By: Michael J. Bruner, Reg. No. 47,458*

By: Michael J. Bruner (Reg. No. 47,458)

**JONES DAY**

222 East 41st Street

New York, New York 10017

(404) 581-8614

For: Anthony M. Insogna (Reg. No. 35,203)

**JONES DAY**

12750 High Bluff Drive, Suite 300

San Diego, California 92130

(858) 314-1130

Enclosures

Substitute for Form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10624-133-999	10/673,121
	APPLICANT	CONF. NO.
	Bhagwat et al.	1280
	FILING DATE	GROUP
	September 26, 2003	1617



## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

A01	Burgess <i>et al.</i> , 1998, "Regulation of the <i>c-jun</i> Gene in p210 BCR-ABL Transformed Cells Corresponds With Activity of JNK, the <i>c-jun</i> N-Terminal Kinase," <i>Blood</i> 92(7):2450-2460.
A02	Cripe <i>et al.</i> , 2002, "Role for <i>c-jun</i> N-terminal kinase in treatment-refractory acute myeloid leukemia (AML) signaling to multidrug-efflux and hyperproliferation," <i>Leukemia</i> 16: 799-812.
A03	Hess <i>et al.</i> , 2002, Survival signaling mediated by c-Jun NH <sub>2</sub> -terminal kinase in transformed B lymphoblasts," <i>Nature Genetics</i> 32:201-205.
A04	Bost <i>et al.</i> , 1999, "The Jun Kinase 2 Isoform Is Preferentially Required for Epidermal Growth Factor-Induced Transformation of Human A549 Lung Carcinoma Cells," <i>Molecular and Cellular Biology</i> 19(3):1938-1949
A05	Yang <i>et al.</i> , 2003, "C-Jun NH <sub>2</sub> -terminal Kinase Mediates Proliferation and Tumor Growth of Human Prostate Carcinoma," <i>Clinical Cancer Research</i> 9:391-401.
A06	Tsuuiki <i>et al.</i> , 2003, "Constitutively Active Forms of c-Jun NH <sub>2</sub> -terminal Kinase Are Expressed in Primary Glial Tumors," <i>Cancer Research</i> 63:250-255.
A07	Potapova <i>et al.</i> , 2000, "c-Jun N-terminal Kinase Is Essential for Growth of Human T98G Glioblastoma Cells," <i>J. Biol. Chem.</i> 275(32):24767-24775.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.